Atorvastatin drug interactions
Pro Research Analysisby 
Searched over 200M research papers
Atorvastatin Drug Interactions: Key Mechanisms and Clinical Implications
CYP3A4 Inhibitors and Inducers: Major Impact on Atorvastatin Levels
Atorvastatin is primarily metabolized by the liver enzyme CYP3A4. Drugs that inhibit CYP3A4, such as certain antiretrovirals (ARVs), can significantly increase atorvastatin blood levels, raising the risk of side effects like muscle toxicity and rhabdomyolysis. For example, boosted ARVs can double atorvastatin exposure, suggesting that the starting dose should be reduced by half when used together and adjusted based on patient response . Conversely, drugs that induce CYP3A4 can lower atorvastatin levels, potentially reducing its effectiveness Courlet2020Zhang2015.
OATP1B1/1B3 Transporter Inhibition: Enhanced Atorvastatin Exposure
Atorvastatin’s uptake into the liver is facilitated by the OATP1B1/1B3 transporters. Inhibitors of these transporters, such as cyclosporine and sildenafil, can greatly increase atorvastatin exposure. For instance, coadministration with cyclosporine can increase atorvastatin levels up to 7- to 9-fold, significantly raising the risk of adverse effects Salem2020Minami2020Li2019. Sildenafil may also inhibit OATP1B1, contributing to increased atorvastatin levels and risk of rhabdomyolysis, especially when used at higher or repeated doses .
Drug-Drug Interactions with Antiretrovirals
People living with HIV often take ARVs that can interact with atorvastatin. Boosted ARVs (those combined with ritonavir or cobicistat) decrease atorvastatin clearance and increase its blood levels, while ARVs that induce CYP3A4 can lower atorvastatin exposure . However, not all ARVs have significant interactions; for example, doravirine does not meaningfully affect atorvastatin pharmacokinetics, making their combination generally safe .
Interactions with Other Common Medications
- Sildenafil: When taken with atorvastatin, especially at higher doses, sildenafil can increase atorvastatin levels and the risk of muscle toxicity due to shared metabolism and transporter inhibition .
- Dronedarone: Atorvastatin and its metabolite can inhibit the metabolism of dronedarone via CYP3A4, potentially altering the effects of both drugs .
- Metformin: No clinically relevant pharmacokinetic interaction is observed when atorvastatin is co-administered with metformin, even in fixed-dose combination tablets .
- Omega-3 Fatty Acids: There is evidence of a pharmacokinetic interaction between atorvastatin and omega-3 fatty acids, but the clinical significance of this interaction requires further study .
Food and Atorvastatin Absorption
Food can delay the absorption of atorvastatin and decrease its peak concentration, but these changes are consistent with those seen when atorvastatin is taken alone and are not considered clinically significant .
Clinical Recommendations
Due to the significant variability in how individuals process atorvastatin, especially when combined with other drugs, careful dose adjustment and monitoring are recommended when starting or stopping medications known to interact with atorvastatin. Clinicians should be particularly cautious with CYP3A4 and OATP1B1/1B3 inhibitors, and consider dose reductions or alternative therapies as needed Courlet2020Salem2020Minami2020+2 MORE.
Conclusion
Atorvastatin is subject to important drug-drug interactions, mainly through CYP3A4 metabolism and OATP1B1/1B3 transport. Inhibitors of these pathways can greatly increase atorvastatin exposure and risk of side effects, while inducers can reduce its effectiveness. Not all drugs interact significantly, but careful review and monitoring are essential when combining atorvastatin with other medications, especially in populations with complex treatment regimens.
Sources and full results
Most relevant research papers on this topic
Species differences in the drug-drug interaction between atorvastatin and cyclosporine: In vivo study using a stable isotope-IV method in rats and dogs.
The drug-drug interaction between atorvastatin and cyclosporine is significantly enhanced in dogs due to decreased hepatic clearance and increased intestinal metabolism, which can help predict its extent in humans.
DOI
Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for atorvastatin and its metabolites.
The developed PBPK model accurately predicts atorvastatin's pharmacokinetic profiles and drug-drug interactions, aiding in assessing its safety and efficacy in the clinic.
DOI